(Q45306207)

English

Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial (English)

1 reference

Europe PubMed Central

11 December 2017

0 references

0 references

hospitalization

1 reference

based on heuristic

inferred from title

failure analysis

1 reference

based on heuristic

inferred from title

ejection fraction

1 reference

based on heuristic

inferred from title

Acute decompensated heart failure

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

11 December 2017

Aldo P. Maggioni

8

1 reference

Europe PubMed Central

11 December 2017

object named as

Haris Subacius

6

0 references

object named as

Mary J Kwasny

5

0 references

object named as

Nicolas Girerd

1

0 references

Mihai Gheorghiade

9

object named as

Mihai Gheorghiade

1 reference

Europe PubMed Central

11 December 2017

10

object named as

Faiez Zannad

1 reference

Europe PubMed Central

11 December 2017

3

object named as

Karl Swedberg

1 reference

Europe PubMed Central

11 December 2017

Marvin A. Konstam

7

object named as

Marvin A Konstam

1 reference

Europe PubMed Central

11 December 2017

Angela J. Fought

4

object named as

Angela Fought

1 reference

Europe PubMed Central

11 December 2017

author name string

EVEREST investigators

11

1 reference

Europe PubMed Central

11 December 2017

publication date

19 June 2013

1 reference

Europe PubMed Central

11 December 2017

European Journal of Heart Failure

1 reference

Europe PubMed Central

11 December 2017

15

1 reference

Europe PubMed Central

11 December 2017

11

1 reference

Europe PubMed Central

11 December 2017

1228-1235

1 reference

Europe PubMed Central

11 December 2017

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Eplerenone in patients with systolic heart failure and mild symptoms

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Association between performance measures and clinical outcomes for patients hospitalized with heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Effect of post-myocardial infarction exercise training on the renin-angiotensin-aldosterone system and cardiac function

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Troponin elevation in heart failure prevalence, mechanisms, and clinical implications

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Captopril in heart failure. A double blind controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

The incidence and implications of aldosterone breakthrough

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Diuretic therapy and resistance in congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFT100

21 January 2018

Identifiers

10.1093/EURJHF/HFT100

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45306207&oldid=2074325219"